QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: jpet.106.111542v1 320/2/828    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, P. J. Articles by Patel, M. K. Search for Related Content PubMed PubMed Citation Articles by Jones, P. J. Articles by Patel, M. K.

NEUROPHARMACOLOGY

Hydroxyamide Analogs of Propofol Exhibit State-Dependent Block of Sodium Channels in Hippocampal Neurons: Implications for Anticonvulsant Activity

Departments of Chemistry (P.J.J., Y.W., H.S.E., M.L.B.), Anesthesiology (N.J.H., M.K.P.), Neurology (J.K.), and Neuroscience Graduate Program (N.J.H.), University of Virginia, Charlottesville, Virginia; and Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (M.D.S., H.S.W.), University of Utah, Salt Lake City, Utah

Received July 26, 2006; accepted November 6, 2006.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Although propofol is most commonly known for its general anesthetic properties, at subanesthetic doses, propofol has been effectively used to suppress seizures during refractory status epilepticus, a mechanism, in part, attributed to the inhibition of neuronal sodium channels. In this study, we have designed and synthesized two novel analogs of propofol, HS245 [2-(3-ethyl-4-hydroxy-5-isopropyl-phenyl)-3,3,3-trifluoro-2-hydroxy-propionamide] and HS357 [2-hydroxy-8-(4-hydroxy-3,5-diisopropyl-phenyl)-2-trifluoromethyl-octanoic acid amide], and determined their effects on sodium currents recorded from cultured hippocampal neurons. HS357 had greater affinity for the inactivated state of the sodium channel than propofol and HS245 (0.22 versus 0.74 and 1.2 µM, respectively) and exhibited the greatest ratio of affinity for the resting over the inactivated state. HS357 also demonstrated greater use-dependent block and delayed recovery from inactivation in comparison with propofol and HS245. Under current-clamp conditions, action potentials from hippocampal CA1 neurons in slices were evoked by current injection, or following perfusion with a zero Mg²⁺/7 mM K⁺ artificial cerebrospinal fluid solution. Propofol and HS357 reduced the number of current-induced action potentials; however, HS357 caused a greater reduction in the number of spontaneous action potentials. Consistent with these electrophysiology studies, propofol and HS357 protected mice against acute seizures in the 6-Hz (22-mA) partial psychomotor model. Efficacious doses of propofol were associated with an impairment of motor coordination as assessed in the rotorod toxicity assay. In contrast, HS357 demonstrated a 2-fold greater protective index than propofol. Thus, propofol analogs represent an important structural class from which not only effective, but also safer, anti-convulsants may be developed.

Voltage-gated sodium channels play an important role in determining neuronal excitability and, therefore, constitute a proven target for the suppression of epileptic seizures. Sodium channels consist of a pore-forming subunit and auxiliary subunits, which modulate the gating kinetics of the channel (Catterall, 2000). To date, nine subunit isoforms and four subunits have been cloned (Goldin, 2001). At hyperpolarized membrane potentials, sodium channels exist in the closed state and transition through the open and into the inactivated state upon membrane depolarization (Goldin, 2003). Clinically used sodium channel blockers are state-dependent; that is, they bind with higher affinity to the inactivated state of the sodium channel than the resting state (Hille, 1977). This state dependence not only is considered important for seizure suppression but also is essential for a favorable side effect profile since it allows AEDs to inhibit action potential (AP) bursts that occur during seizures without affecting normal neuronal activity (Hille, 1977; Rogawski and Loscher, 2004).

Propofol (2,6-diisopropylphenol) is most commonly known for its use as an i.v. general anesthetic; however, at subanesthetic doses, propofol is used clinically during refractory status epilepticus, a critical medical emergency with mortality rates as high as 76% in elderly patients (Prasad et al., 2001; Claassen et al., 2002; Marik and Varon, 2004; Rossetti et al., 2004). Propofol has been shown to inhibit sodium currents in mammalian cell lines expressing rat Na_v1.2 (Rehberg and Duch, 1999), to activate GABA currents in hippocampal neurons (Orser et al., 1994), and to inhibit L-type calcium currents in cortical neurons (Martella et al., 2005). However, its modulation of sodium currents (Martella et al., 2005) has been suggested to be important for its AED activity in both veratridine-induced seizures (Otoom and Hasan, 2004) and amygdala-kindled rats (Borowicz and Czuczwar, 2003). Although the mechanisms of action for propofol remain unclear, it continues to be an effective alternative to barbiturates and first line AEDs when treating refractory status epilepticus (Rossetti et al., 2004).

In this study, we have used propofol as a scaffold to design novel analogs. The first propofol analog, HS245, incorporates an -hydroxyamide moiety we have shown previously to be important for sodium channel inhibition (Brown et al., 1999; Lenkowski et al., 2004). In a previous study, we have also shown that the replacement of one phenyl ring in the structure of phenytoin with a seven-carbon alkyl chain resulted in a potent and state-dependent sodium channel blocker (Lenkowski et al., 2004). To further determine the optimum distance between the phenyl and -hydroxyamide moieties, we designed HS357, which incorporates a six-carbon alkyl linker (Fig. 1).

View larger version (17K): [in this window] [in a new window]   Fig. 1. Compound structures and design. Propofol, HS245, and HS357 are examined in this study. HS245 includes a hydroxyamide moiety, whereas HS357 incorporates a six-carbon linker between the phenyl and hydroxyamide moieties.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. Propofol was obtained from Sigma-Aldrich (St. Louis, MO). HS245 and HS357 were synthesized as described in the supplemental data.

Hippocampal Culture. All experimental protocols were approved by the Institutional Animal Care and Use Committee affiliated with the University of Virginia and the University of Utah. All efforts were made to minimize animal stress and discomfort. The preparation of hippocampal cultures has been described previously (Mangan and Kapur, 2004). Briefly, hippocampi were dissected from 18-day-old rat embryos, dissociated by trypsin, and triturated with a Pasteur pipette. The neurons were plated on coverslips coated with poly-L-lysine in minimal essential medium with 10% horse serum at an approximate density of 25,000/cm². Once the neurons had attached to the substrate, they were transferred to a dish containing a glial monolayer and maintained for up to 4 weeks in serum-free minimal essential medium with N2 supplement. Voltage-clamp recordings were made from 1- to 2-week-old cultured hippocampal neurons.

Brain Slice Preparation. Transverse hippocampal slices (250–300 µm) were prepared from Sprague-Dawley rats (150–200 g). Animals were euthanized with halothane and decapitated, and brains were rapidly removed and placed in chilled (4°C) ACSF containing 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH₂PO₄, 2 mM CaCl₂, 1 mM MgCl₂, 0.5 mM L-ascorbic acid, 10 mM glucose, 25 mM NaHCO₃, and 2 mM pyruvate (oxygenated with 95% O₂ and 5% CO₂). Slices were prepared using a Vibratome (Vibratome 1000 Plus, St. Louis, MO) and transferred to a chamber containing oxygenated ACSF, incubated at 37°C for 20 to 35 min, and then stored at room temperature. For recording, slices were held in a small chamber perfused with heated (32°C) oxygenated ACSF at 2 ml/min. CA1 hippocampal neurons were visually identified using a Zeiss Axioscope microscope (Zeiss, Oberkochen, Germany).

Electrophysiology. Sodium currents were recorded from cultured hippocampal neurons using the whole-cell configuration of the patch clamp recording technique with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA). All voltage protocols were applied using Clampfit software (version 9; Axon Instruments) and a Digidata 1322A (Axon Instruments). Currents were acquired at 33 kHz and low-pass filtered at 2 kHz. Borosilicate glass pipettes were pulled using a Brown-Flaming puller (model P-87; Sutter Instruments Co., Novato, CA) and heat polished to produce electrode resistances of 1.5 to 2.0 M when filled with pipette solution containing 140 mM CsF, 2 mM MgCl₂, 1 mM EGTA, 10 mM HEPES, 4 mM Na₂ATP, and 0.3 mM NaGTP, pH adjusted to 7.3 with CsOH. Cultured neurons were perfused with solution containing 30 mM NaCl, 110 mM choline chloride, 3 mM KCl, 1 mM CaCl₂, 0.1 mM CdCl₂, 2 mM MgCl₂, 10 mM HEPES, and 30 mM TEA-Cl, pH adjusted to 7.3 with CsOH. Calcium and potassium currents were blocked by cadmium and TEA-Cl, respectively. On establishing the whole-cell configuration, neurons were held at –90 mV for 5 min to permit time for the equilibration of gating shifts. Currents were elicited from a holding potential of –90 mV by a step to –10 mV for 20 ms. Capacitive and leak currents were corrected for using standard P/4 protocols except during steady-state inactivation and use-dependent block protocols. All voltage clamp experiments were performed at room temperature (20–22°C). Current-clamp recordings were performed at 32°C in an ACSF extracellular solution described previously and an intracellular solution containing 120 mM potassium gluconate, 10 mM NaCl, 2 mM MgCl₂, 0.5 mM K₂EGTA, 10 mM HEPES, 4 mM NaATP, and 0.3 mM NaGTP, pH adjusted to 7.2 with KOH.

To induce spontaneous firing in hippocampal CA1 pyramidal neurons, slices were perfused (20 min) with a nominally zero Mg²⁺/7 mM K⁺ ACSF solution containing 125 mM NaCl, 7 mM KCl, 1.25 mM NaH₂PO₄, 2 mM CaCl₂, 25 mM NaHCO₃, and 10 mM glucose (oxygenated with 95% O₂ and 5% CO₂), and the same intracellular solution was used for AP current-clamp recordings with the removal of MgCl₂. Compounds were prepared as 100 mM stock solutions in dimethylsulfoxide (DMSO) and diluted to desired concentrations in the respective extracellular solution. The total concentration of DMSO was maintained at less than 0.2% of the total volume.

Data Analysis. IC₅₀ values were obtained by least-squares fitting of data to the Hill equation:

(1)

where C is the concentration, IC₅₀ is the concentration that blocks 50% of the current, I is the current in presence of the drug, I_control is the current in the absence of drug, and n_H is the Hill slope. Steady-state inactivation data were fitted to a Boltzmann equation of the form:

(2)

where I/I_max is the normalized current, I_max is the maximum current, V_1/2 is the voltage of half-maximal inactivation, and k is the slope factor. The difference between the V_1/2 value in the presence and absence of compound is shown as V_1/2 (millivolts).

The affinities for the inactivated states of the channel were calculated using the steady-state inactivation curves in the presence of various concentrations of compound (Bean et al., 1983; Kuo and Bean, 1994), according to the following equation:

(3)

where K_i is the binding affinity for the inactivated state, K_r is the binding affinity for the resting state (calculated from dose-response curves at –90 mV), D is the drug concentration, k is the slope of the steady-state inactivation curve, and V_1/2 is the shift of the steady-state inactivation curve in the presence of drug compared with control.

Time constants for recovery from inactivation were obtained using a double exponential function:

(4)

where A₁ and A₂ are the amplitudes of the fast and slow exponentials, t is the time, and ₁ and ₂ are the fast and slow time constants. The percentage of the current represented by the fast time constant was calculated from the equation:

(5)

Time constants for use-dependent block at 10 Hz were obtained using a single exponential function. Data analysis was performed using Clampfit software (version 9; Axon Instruments), Origin (version 6; Microcal Origin, Northampton, MA), and Excel (Microsoft Corp., Redmond, WA). Statistical analyses were performed using the standard one-way ANOVA followed by Tukey's post hoc test, or the paired Student's t test (SigmaStat; Systat, Inc., San Jose, CA). Averaged data are presented as mean ± S.E.M. Statistical significance was set at p < 0.05.

Six-Hertz Corneal Stimulation Seizure Model. Adult male CF-1 mice (Charles River Laboratories, Wilmington, MA) weighing between 20 and 30 g were used in all experiments. Anticonvulsant activity was assessed using the 6-Hz partial "psychomotor" seizure model described previously (Barton et al., 2001). Briefly, seizure activity was evoked via corneal stimulation (6 Hz, 0.2-ms rectangular pulse width, 3-s duration, 22 mA) using a Grass S48 stimulator (Grass Instruments, Berkshire, UK). A drop of 0.5% tetracaine anesthetic was applied directly to the eyes of all animals at the time of test compound administration. At the time of peak effect (TPE) for each compound, a drop of 0.9% saline was placed on each eye before corneal electrode placement. After stimulation, mice were observed for the presence or absence of behaviors consistent with partial seizure activity (immobility, forelimb clonus, twitching of the vibrissae, and Straub tail). All compounds were administered i.p. in a volume of 0.01 ml/g body weight. Drugs were dissolved in 0.5% (w/v) methylcellulose or 0.9% sodium chloride. If a test compound did not produce a suitable suspension in methylcellulose or sodium chloride, then Tween 80 (not to exceed one to two drops) and/or DMSO (<1% total volume) was used. Protection was defined as the absence of a seizure, whereas toxicity was defined as impairment of motor coordination assessed in the rotorod assay. Impairment was defined as the inability of a mouse to maintain equilibrium in three consecutive trials during a 1-min test on a rod rotating at 6 rpm. For each compound we evaluated the TPE, ED₅₀, and TD₅₀ values. The TPE was determined by assessing the protection by propofol (30 mg/kg) and HS357 (100 mg/kg) at 5, 10, 15, 30, 60, and 120 min after i.p. administration. The protective index (PI) value is defined as the ratio TD₅₀/ED₅₀ and was calculated for each test compound. At the conclusion of each experiment, animals were sacrificed in accordance with the guidelines established by the Institute of Laboratory Resources and the University of Utah's policy on the humane care and use of laboratory animals.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Propofol and Analogs Block Sodium Currents in Hippocampal Neurons. The chemical structures of propofol, HS245, and HS357 are shown in Fig. 1. We have previously shown that the replacement of the methyl group in themisone, an anticonvulsant used in the 1940s, with a trifluoro group yielded a compound with potent anticonvulsant activity in the maximal electric shock animal model of epilepsy (Choudhury-Mukherjee et al., 2003) (Fig. 1). In this study, we have continued to investigate the importance of both the triflouro and the -hydroxyamide groups of this themisone analog. Although HS245 explores the functional consequences of overlapping the phenyl rings of propofol with our themisone analog, HS357 explores the effects of separating the phenyl and the triflouro/-hydroxyamide portions of HS245 with a six-carbon alkyl linker (Fig. 1). Previous comparative molecular field analysis modeling studies have suggested that compounds with longer alkyl chains have an increased affinity for the inactivated state of the cardiac sodium channel (Lenkowski et al., 2004). Interestingly, the structural changes made to the propofol scaffold resulted in different lipophilicity values (log Ps) for propofol, HS245, and HS357 (3.63, 3.43, and 5.74, respectively).

Propofol and Derivatives Affinities for the Inactivated State. To determine the affinity for the resting state of the sodium channel, concentration-dependent curves were generated at a negative holding membrane potential of –90 mV (Fig. 2). When data were fit to the Hill equation, the IC₅₀ at –90 mV (K_r) values for propofol, HS245, and HS357 were 17.7, 100, and 24 µM with corresponding Hill slopes of 0.98, 1.84, and 1.50, respectively (Fig. 2A). Interestingly, both HS245 and HS357 had Hill slopes greater than 1, suggesting that the compounds could be interacting with more than one binding site. Example current traces are shown in Fig. 2B.

View larger version (28K): [in this window] [in a new window]   Fig. 2. Tonic block of sodium currents by propofol and analogs in cultured hippocampal neurons. A, concentration-dependent inhibition of sodium currents by propofol, HS245, and HS357. Currents were elicited by a step depolarization to –10 mV for 20 ms from a holding potential of –90 mV. Data represent the mean ± S.E.M. Smooth lines represent the least-squares fit when data were fitted with the Hill equation. The values in parentheses represent the sample size for each data point. B, representative current traces for application of propofol and each analog.

View larger version (29K): [in this window] [in a new window]   Fig. 3. Effects of propofol and analogs on steady-state inactivation curves in cultured hippocampal neurons. A to C, from a holding potential of –90 mV, prepulse potentials ranging from –105 to –30 mV were applied for 1 s followed by a depolarization step to –10 mV for 20 ms to elicit a current. Currents were normalized to the peak current elicited from the –105-mV test potential within each experiment. Smooth lines correspond to the average of the least-squares fits when data were fitted by the Boltzmann equation as described in the data analysis section. Propofol (10 µM), V1/2 = –68.3 ± 3.4 mV, k = 5.3 ± 0.3 mV, n = 4; propofol (30 µM), V1/2 = –70.8 ± 1.5 mV, k = 5.2 ± 0.3 mV, n = 4; HS245 (10 µM), V1/2 = –74.5 ± 1.8 mV, k = 5.1 ± 0.2 mV, n = 5; HS245 (30 µM), V1/2 = –81.7 ± 0.9 mV, k = 5.3 ± 0.3 mV, n = 4; HS357 (3 µM), V1/2 = –69.1 ± 2.7 mV, k = 5.4 ± 0.1 mV, n = 7; HS357 (30 µM), V1/2 =–74.9 ± 2.0 mV, k = 5.8 ± 0.3 mV, n = 5. Data points represent the mean ± S.E.M. D, smooth lines correspond to the average of the least-squares fits when data were fitted by the equation V1/2 = k log[1 + (D/Ki)]/[1 + (D/Kr)] to calculate the affinity for the inactivated state (Ki). Data points represent the mean ± S.E.M (n = 4–7).

The affinity for the inactivated state of the channel for each compound was calculated from these concentration-dependent shifts in steady-state inactivation and tonic block data using the equation described previously in the data analysis section (Fig. 3D; Table 1). HS357 demonstrated a greater binding affinity for the inactivated state (K_i = 0.2 µM) compared with propofol (K_i = 0.7 µM), whereas HS245 had a lower binding affinity (K_i = 1.2 µM). Comparing the binding affinity with the resting state versus the inactivated state (K_r/K_i) both HS245 and HS357 exhibited approximately a 4- to 5-fold greater K_r/K_i ratio than their parent compound, propofol (Table 1).

Propofol and Analogs Exhibit Use-Dependent Block. Use-dependent blocking characteristics are thought to be important since they allow further block of sodium channels during sustained high-frequency depolarizations known to occur during seizure activity. To this end, use-dependent block of propofol and our compounds were examined using 10-Hz trains of depolarizing pulses to –10 mV from a holding potential of –90 mV (Fig. 4). Peak current amplitude was normalized to the first pulse in each experiment. Under control conditions, accumulation of inactivated channels resulted in a reduction in peak current amplitude by 30.4 ± 4.6% (n = 16). Propofol and HS357 were both tested at 30 µM, a concentration close to their IC₅₀ values. At these concentrations, propofol and HS357 further reduced the current amplitude by 60.8 ± 3.2% (n = 5) and 79.5 ± 6.6% (n = 6), respectively (p < 0.01) after 6 s. Interestingly, when tested at a concentration lower than its IC₅₀ (30 µM), HS245 exhibited significant (p < 0.01) use-dependent block, reducing the current amplitude to 50.7 ± 8.8% (n = 5). To assess the rate of development of use-dependent block, data were fitted with a single exponential function. Time constants for propofol, HS245, and HS357 were 2 ± 0.2, 2.9 ± 0.7, and 1.6 ± 0.1 s, respectively.

View larger version (25K): [in this window] [in a new window]   Fig. 4. Effects of propofol and derivatives on use-dependent block at 10 Hz in cultured hippocampal neurons. A, currents were elicited by a 20-ms pulse from –90 mV at a frequency of 10 Hz for 6 s. Each peak sodium current was normalized to current amplitude at time = 0.1 s. Values represent the mean ± S.E.M (n = 5–6). B, representative current traces for control and drug conditions. Vertical scale bars, 200 pA; horizontal scale bars, 2 ms.

View larger version (30K): [in this window] [in a new window]   Fig. 5. Effects of propofol and analogs on the recovery from inactivation of sodium currents. Recovery from inactivation was assessed using a two-pulse protocol. A, prepulse from –90 to 0 mV for 1 s was applied to inactivate channels. Subsequently, neurons were then held at –90 mV for a variable period of time (1 ms –100 s) to allow channels to recovery, and then the proportion of recovered channels was assessed with a 20-ms voltage step to –10 mV. Smooth lines correspond to the average of the least-squares fits when data were fitted to a double exponential function as described in the data analysis section. B, representative current traces are shown for control and HS357. Data points represent the mean ± S.E.M. (n = 4–5).

Propofol and HS357 Modulate Membrane Excitability and Epileptiform Activity. In comparison with HS245, the actions of HS357 on sodium channel gating kinetics were more pronounced. In view of this, HS357 was selected to determine its effects on membrane excitability. The effects of propofol and HS357 on AP discharge and key parameters of the AP were determined. Under current-clamp conditions, depolarizing current injections (0.02–0.16 nA, 300 ms) were used to elicit AP discharges in CA1 neurons in hippocampal slices. Typical resting membrane potential values for CA1 neurons under these recording conditions were –64.3 ± 2.4 mV (n = 11) and remained unaltered in the presence of both propofol and HS357. The effects of propofol and HS357 on APs elicited after a 300-ms current injection of 0.14 nA are shown in Fig. 6. Both propofol and HS357 caused a modest reduction in the number of APs evoked. At a concentration of 30 µM, APs were reduced from 6.8 ± 1.2 to 4.3 ± 0.9 (n = 4, p < 0.05) for propofol and from 6.9 ± 1.6 to 4.9 ± 1.6 (n = 7, p < 0.05) for HS357. These effects remained unchanged in the presence of picrotoxin (100 µM), a selective GABA_A antagonist. Under these conditions, HS357 (30 µM) reduced the number of APs from 6.7 ± 0.4 in control to 5.0 ± 0.72 (p < 0.05, n = 3) in the presence of drug. Neither propofol nor HS357 altered input resistance, AP amplitude, AP duration, or afterhyperpolarization amplitude. In contrast to propofol, HS357 increased the rheobase by 20 pA (p < 0.05, n = 7, data not shown). All effects were fully reversible upon washout.

View larger version (17K): [in this window] [in a new window]   Fig. 6. Propofol and HS357 decrease AP discharges in hippocampal CA1 pyramidal neuron slices. Injection of depolarizing current pulses (–0.02 to 0.16 nA, 300 ms) induced reproducible AP discharges under control conditions in CA1 pyramidal neurons. Both propofol (30 µM; A) and HS357 (30 µM; B) caused a modest decrease in firing activity within 10 min of drug perfusion.

To test the effects of propofol and HS357 on sustained spontaneous ictal-like AP discharges, CA1 pyramidal neurons in hippocampal slices were perfused with ACSF containing zero Mg²⁺/7 mM K⁺. The resulting enhanced neuronal excitability is thought to be comparable with epileptiform activity and is partially attributed to increased NMDA receptor activity as a result of reduced magnesium block (Mangan and Kapur, 2004).

The perfusion of hippocampal slices (n = 9) with our modified ACSF solution (zero Mg²⁺/7 mM K⁺) resulted in sustained spontaneous discharges in CA1 pyramidal neurons (Fig. 7). The number of APs spontaneously generated during a 100-s period before perfusion of the test compound was considered as control and was compared with the number of APs elicited in the presence of test compounds and after washout. Under control conditions, the average number of ictal discharges was 42.2 ± 6.5 (n = 9) and was reduced to 13.2 ± 2.7 in the presence of propofol (30 µM, n = 5, p < 0.01). After a 20-min period, only partial washout was observed for propofol (24.5 ± 5.0; Fig. 7A). In comparison, HS357 (30 µM, n = 4, p < 0.01) caused a further reduction in the number of epileptiform events, reducing it to 8.8 ± 2.0, and was completely reversible after a 20-min washout (40.0 ± 15.6). Once again, the effects of HS357 were unaffected by the presence of picrotoxin (100 µM). Specifically, the number of APs counted in a 100-s interval before drug application was 118 ± 40 and was reduced to 19 ± 11 in the presence of both HS357 (30 µM) and picrotoxin (100 µM; p < 0.05, n = 3). Furthermore, this effect, a 84.5 ± 5.9% reduction in the number of AP discharges in the presence of picrotoxin and HS357, was not significantly different (p = 0.79) from those observed in the presence of only HS357 (82.1 ± 8.0% reduction).

View larger version (74K): [in this window] [in a new window]   Fig. 7. Propofol and HS357 inhibit epileptiform activity in CA1 pyramidal neurons. Perfusion of slices with zero Mg2+/7 mM K+ ACSF (20 min) caused the appearance of epileptiform activity in hippocampal CA1 pyramidal neurons. A, representative trace shows perfusion of propofol (30 µM) caused a moderate decrease in the ictal-like discharges that was partially reversible upon wash (20 min). B, representative traces demonstrates perfusion of HS357 (30 µM) caused a marked reduction in ictal-like activity that was fully reversible upon wash (20 min). Expanded time scales of 100 s are shown in the insets and control (i), drug (ii), and wash (iii) conditions are indicated for both propofol and HS357 experiments.

Anticonvulsant Activity and Toxicity of Propofol and HS357. To determine whether the modulation of sodium channel gating and decreased neuronal excitability observed in vitro would translate into anticonvulsant activity in vivo, test compounds were administered systemically to male CF-1 mice and tested in the 6-Hz (22-mA stimulation) partial psychomotor seizure model. Behavioral signs of toxicity were assessed using the mouse rotorod assay (Table 3). TPEs of 1.0 h for HS357 and approximately 5 min for propofol were determined after i.p. administration of the compounds. At their respective TPEs, both propofol and HS357 prevented partial seizure activity in the 6-Hz test. The ED₅₀ observed after i.p. administration of propofol (15.8 mg/kg) was 2.8-fold lower than that observed for HS357 (56.3 mg/kg). However, the protection afforded by propofol was associated with significant sedation and motor impairment, which resulted in a TD₅₀ of 18.0 mg/kg, consistent with propofol's anesthetic properties. In contrast, HS357 was observed to be profoundly less toxic, as indicated by its 9-fold higher TD₅₀ (155.7 mg/kg) than propofol. The observed ED₅₀ and TD₅₀ values for propofol and HS357 resulted in estimated PIs of 1.1 and 2.7, respectively. Taken together, these results demonstrate that HS357 not only exhibits anticonvulsant activity in the 6-Hz (22 mA) psychomotor seizure model but also possesses fewer toxic side effects than propofol.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Propofol at subanesthetic concentrations exhibits anticonvulsant properties in refractory status epilepticus patients (Brown and Levin, 1998; Prasad et al., 2001; Rossetti et al., 2004). However, several studies have cautioned against the use of propofol as an anticonvulsant because of serious side effects (Claassen et al., 2002; Marik, 2004). Although propofol is known to enhance GABA currents and inhibit Ca²⁺ channels, its modulation of neuronal sodium channels is thought to be a major determinant for its AED activity (Orser et al., 1994; Rehberg and Duch, 1999; Martella et al., 2005). In this study, we have synthesized two novel analogs of propofol and characterized their effects on sodium channel gating. One of the propofol derivatives, HS357, inhibited spontaneously generated APs and protected against seizures generated in 6-Hz (22 mA) psychomotor model with less behavioral toxicity than propofol.

Biophysical Properties of Propofol Analogs Parallel Physicochemical and Structural Properties. Propofol caused tonic inhibition of sodium channel currents recorded from cultured hippocampal neurons with an IC₅₀ value of 17 µM, consistent with values reported for Na_v1.2 -subunits expressed in Chinese hamster ovary cells (Rehberg and Duch, 1999). In contrast, addition of an -hydroxyamide to the phenyl ring of propofol resulted in HS245 and a 5-fold lower affinity for the resting state but only a 1.6-fold difference in affinity for the inactivated state. Interestingly, HS357, which incorporates an alkyl linker between the amide and phenyl groups, exhibited a comparable resting state inhibition with that of propofol but a 3.6-fold greater affinity for the inactivated state compared with propofol. These distinct biophysical properties observed for propofol and its derivatives may parallel differences in their physicochemical and structural properties. First, it is possible that direct addition of the -hydroxyamide moiety to the phenyl ring of propofol destabilizes the molecular interactions of HS245 with the closed state of the channel, whereas it has little effect on interactions formed with the inactivated state (Table 1). The addition of the -hydroxyamide moiety to HS245 would increase the steric bulk around the phenyl group, and this could provide steric hindrance for HS245, allowing a less favored interaction with the resting state binding site. Conversely, addition of the aliphatic chain in HS357 affords a greater distance between the bulky -hydroxyamide moiety and the phenyl ring, which could explain the similarity of HS357's resting state affinity to that of propofol. In support of this hypothesis, mutagenesis studies have shown that replacing the large hydrophobic residues L1465, N1466, and I1469 in D3-S6 with the smaller amino acid, alanine, caused a 2-fold increase in the resting state block by lamotrigine (Yarov-Yarovoy et al., 2001). This increase in resting state block by lamotrigine was attributed to additional space made available for access to the resting state binding site.

The second distinct structural feature of HS357 is its greater spatial volume compared with propofol and HS245, which could be important for HS357's increased affinity for the inactivated state. The addition of the alkyl chain adds approximately 10.3 Å between the phenyl and -hydroxyamide moieties of HS357. It has been proposed that the local anesthetic/AED binding site is approximately 10 Å in length (Lipkind and Fozzard, 2005) and becomes more accessible to larger molecules upon proposed conformational changes of S6 segments during activation (Yarov-Yarovoy et al., 2001, 2002). Given that HS357 is at least 10.3 Å in length, it would nearly occupy the entire binding site and thereby allow for stronger and more confined - stacking interactions between the phenyl and aromatic residues within the receptor site. Potential interaction sites are likely to be the aromatic residues F1764 and Y1771 on D4-S6, which are critical for binding of AEDs, local anesthetics, and other therapeutic agents (Ragsdale et al., 1996; Ragsdale and Avoli, 1998; Yarov-Yarovoy et al., 2001; Nau and Wang, 2004). In addition to these sites, it is also possible that the alkyl side chain of HS357 could form hydrophobic interactions sites with more distant residues such as L1465 and I1469 in D3-S6. These amino acids have also been suggested to form part of the AED and local anesthetic binding site (Yarov-Yarovoy et al., 2001). In fact, mutation of these residues to alanine decreased the affinity for the inactivated state for lamotrigine, its derivatives, and etidocaine (Ragsdale et al., 1994, 1996; Yarov-Yarovoy et al., 2001, 2002).

Finally, HS357 possesses a greater log P than propofol and HS245. An increase in lipophilicity values may contribute to HS357's ability to readily form hydrophobic interaction within the AED binding site, consequently allowing stronger binding constants. Several studies have correlated increased log P values with increased sodium channel inhibition; indicating that hydrophobic interactions may be formed by sodium channel blockers (Brown et al., 1997; Yarov-Yarovoy et al., 2001; De Luca et al., 2003).

Greater Inhibition of Epileptiform Discharges by Propofol Analog. Under current-clamp conditions, we determined the effects of propofol and HS357 on both evoked APs by current injection and spontaneously occurring APs induced by the perfusion of a zero Mg²⁺/7 mM K⁺ ACSF solution. Spontaneous APs generated by perfusion of zero Mg²⁺ are thought to be a useful model of seizure activity in epileptic patients (Rafiq et al., 1995; Derchansky et al., 2004). Furthermore, clinically used AEDs such as valproate, gabapentin, and carbamazepine have demonstrated efficacy in this in vitro hyperexcitability model (Arias and Bowby, 2005). Both propofol and HS357 exhibited more pronounced block of epileptiform events than current-evoked APs. These results are consistent with previous studies showing selective inhibition by propofol of low Mg²⁺-induced epileptiform activity over current-evoked APs in cortical neurons (Martella et al., 2005). In these studies, bicuculline abolished the effects of propofol on current-evoked APs but not on low Mg²⁺-induced APs. In contrast, HS357's effects on both current-evoked APs and low Mg²⁺-induced APs were unchanged in the presence of picrotoxin, a selective GABA_A antagonist, suggesting that HS357's actions were not mediated by the potentiation of GABA currents. However, effects on other ion channel targets cannot be ruled out.

During spontaneous epileptic events, sodium channels rapidly cycle through the closed, activated, and inactivated states. According to the modulated receptor hypothesis (Hille, 1977), sodium channels accumulate in high-affinity drug binding conformations (i.e., open and/or inactivated states) and therefore the inhibitory effects of propofol and HS357 on epileptiform events may be explained by their greater affinities for the inactivated state. HS357's more pronounced inhibition of epileptic events compared to propofol could be attributed to its 4-fold greater K_r/K_i ratio than propofol, resulting in greater use-dependent block and further delay of recovery from inactivation. These mechanisms would reduce sodium channel availability during high-frequency repetitive firing (Ragsdale and Avoli, 1998; Rogawski and Loscher, 2004).

In Vivo Studies and Therapeutic Implication for a Novel Propofol Analog. Our behavioral studies in the 6-Hz partial seizure model support our hypothesis that structural changes in the propofol scaffold can result in novel compounds with anticonvulsant activity. At efficacious doses (30 mg/kg), propofol caused marked sedation and ataxia, whereas HS357 (100 mg/kg) displayed little or no side effects at higher doses. The approximate 2-fold difference in PI values for propofol and HS357 may again be attributed to HS357's far greater selectivity for the inactivated over resting state of the sodium channel (i.e., K_r/K_i ratios). In other words, increased K_r/K_i ratios for sodium channel blockers may indicate greater in vivo efficacy with fewer side effects by favoring a block of sustained high-frequency firing, which is known to occur during epileptic activity, without interfering with normal neuronal firing.

The greater protective index of HS357 is a desirable characteristic for a potential AED and warranted in the therapeutic treatment of seizure suppression (Brodie, 2001). Equally important to improved tolerability is the identification of new AEDs with potential efficacy in therapy resistance patients (Brodie, 2001). Previous studies have implicated the use of the 6-Hz model (22–44 mA) for identifying potentially useful AEDs and differentiating those that may be effective for patients with therapy-resistant epilepsies (Barton et al., 2001). For example, levetiracetam, an AED used to treat refractory human partial seizures, was effective in the 6-Hz model (22, 32, and 44 mA) but inactive in the maximal electroshock and s.c. metrazole seizure models (Barton et al., 2001). Other anticonvulsant agents, including phenytoin, lamotrigine, and ethosuximide, were effective at blocking seizures in the 6-Hz model at 22 mA but were unable to maintain this protection at 32 mA (phenytoin, lamotrigine) or at 44 mA (ethosuximide). Here, we show that HS357 is not only effective in the 6-Hz model at 22 mA but also better tolerated than its parent compound, propofol. Given the activity identified at the 22-mA current intensity, it will be important to determine the potential utility of HS357 and/or propofol in the 6-Hz partial seizure model at higher current intensities to determine whether these compounds would offer any potential benefit for refractory seizure activity.

In summary, clinical and experimental results have established sodium channel blockers as effective treatments of epilepsy. Here, we describe the effects of propofol and two derivatives, HS245 and HS357, on sodium currents recorded from hippocampal neurons. HS357 demonstrated a greater affinity for the inactivated state of the sodium channel and protected mice against seizures in the 6-Hz seizure model. Furthermore, HS357 displayed a greater safety margin than propofol with regards to impairment of motor coordination, suggesting that propofol analogs could be an important structural class in the development of new AEDs.

	Acknowledgements

 
We thank the Cardiovascular Research Center at the University of Virginia (M.K.P. and P.J.J.) and acknowledge Ashley E. Renick, Hannelore D. Assmussen, and Ashley K. McCusker for providing cultured hippocampal neurons. In addition, we acknowledge the support of James P. Stables and the Anticonvulsant Screening Project, National Institute of Neurological Disorders and Stroke, National Institutes of Health for initial in vivo evaluations of HS245 and HS357. We also thank Carl Lynch III and Birgit Priest for helpful comments and advice on the manuscript.

	Footnotes

 
This work was supported by the National Institutes of Health (Grants RO1 CA 105435-01 to M.L.B. and M.K.P. and N01-NS-4-2359 to M.D.S. and H.S.W.), by Predoctoral Training in Neuroscience (Grant 5 T32 GM008328 to N.J.H.), and by the United Negro College Fund/Merck Science Initiative Graduate Dissertation Fellowship (to P.J.J.).

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.106.111542.

ABBREVIATIONS: AED, antiepileptic drug; AP, action potential; HS245, 2-(3-ethyl-4-hydroxy-5-isopropyl-phenyl)-3,3,3-trifluoro-2-hydroxypropionamide; HS357, 2-hydroxy-8-(4-hydroxy-3,5-diisopropyl-phenyl)-2-trifluoromethyl-octanoic acid amide; ACSF, artificial cerebrospinal fluid; DMSO, dimethyl sulfoxide; ANOVA, analysis of variance; TPE, time of peak effect; PI, protective index.

The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

Address correspondence to: Dr. Manoj K. Patel, Department of Anesthesiology, University of Virginia Health Systems, 1 Hospital Drive, Old Medical School, Charlottesville, VA 22908. E-mail: mkp5u{at}virginia.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Arias RL and Bowby MR (2005) Pharmacological characterization of antiepileptic drugs and experimental analgesics on low magnesium-induced hyperexcitability in rat hippocampal slices. Brain Res 1047: 233–244.[CrossRef][Medline]

Barton ME, Klein BD, Wolf HH, and White HS (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217–227.[CrossRef][Medline]

Bean BP, Cohen CJ, and Tsien RW (1983) Lidocaine block of cardiac sodium-channels. J Gen Physiol 81: 613–642.[Abstract/Free Full Text]

Borowicz KK and Czuczwar SJ (2003) Effects of etomidate, ketamine or propofol, and their combinations with conventional antiepileptic drugs on amygdala-kindled convulsions in rats. Neuropharmacology 45: 315–324.[CrossRef][Medline]

Brodie MJ (2001) Do we need any more new antiepileptic drugs? Epilepsy Res 45:- 6.

Brown LA and Levin GM (1998) Role of propofol in refractory status epilepticus. Ann Pharmacother 32: 1053–1059.[Abstract]

Brown ML, Brown GB, and Brouillette WJ (1997) Effects of Log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J Med Chem 40: 602–607.[CrossRef][Medline]

Brown ML, Zha CC, Van Dyke CC, Brown GB, and Brouillette WJ (1999) Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem 42: 1537–1545.[CrossRef][Medline]

Browne TR and Holmes GL (2001) Primary Care: Epilepsy. New Engl J Med 344: 1145–1151.[Free Full Text]

Catterall WA (2000) From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26: 13–25.[CrossRef][Medline]

Chen Y, Yu FH, Surmeier DJ, Scheuer T, and Catterall WA (2006) Neuromodulation of Na⁺ channel slow inactivation via CAMP-dependent protein kinase and protein kinase C. Neuron 49: 409–420.[CrossRef][Medline]

Choudhury-Mukherjee J, Schenck HA, Cechova S, Pajewski TN, Kapur J, Ellena J, Cafiso DS, and Brown ML (2003) Design, synthesis, and evaluation of analogues of 3,3,3-trifluoro-2-hydroxy-2-phenyl-propionamide as orally available general anesthetics. J Med Chem 46: 2494–2501.[CrossRef][Medline]

Claassen J, Hirsch LJ, Emerson RG, and Mayer SA (2002) Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 43: 146–153.[Medline]

De Luca A, Talon S, De Bellis M, Desaphy JF, Lentini G, Corbo F, Scilimati A, Franchini C, Tortorella V, and Camerino DC (2003) Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol Pharmacol 64: 932–945.[Abstract/Free Full Text]

Derchansky M, Shahar E, Wennberg RA, Samoilova M, Jahromi SS, Abdelmalik PA, Zhang L, and Carlen PL (2004) Model of frequent, recurrent, and spontaneous seizures in the intact mouse hippocampus. Hippocampus 14: 935–947.[CrossRef][Medline]

Goldin AL (2001) Resurgence of sodium channel research. Annu Rev Physiol 63: 871–894.[CrossRef][Medline]

Goldin AL (2003) Mechanisms of sodium channel inactivation. Curr Opin Neurobiol 13: 284–290.[CrossRef][Medline]

Hille B (1977) Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 69: 497–515.[Abstract/Free Full Text]

Kuo CC and Bean BP (1994) Slow binding of phenytoin to inactivated sodium-channels in rat hippocampal-neurons. Mol Pharmacol 46: 716–725.[Abstract]

Lenkowski PW, Ko SH, Anderson JD, Brown ML, and Patel MK (2004) Block of human Na(V)1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci 21: 635–644.[CrossRef][Medline]

Lipkind GM and Fozzard HA (2005) Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol 68: 1611–1622.[Abstract/Free Full Text]

Loscher W and Schmidt D (2002) New horizons in the development of antiepileptic drugs. Epilepsy Res 50: 3–16.[CrossRef][Medline]

Mangan PS and Kapur J (2004) Factors underlying bursting behavior in a network of cultured hippocampal neurons exposed to zero magnesium. J Neurophysiol 91: 946–957.[Abstract/Free Full Text]

Marik PE (2004) Propofol: therapeutic indications and side-effects. Curr Pharm Des 10: 3639–3649.[CrossRef][Medline]

Marik PE and Varon J (2004) The management of status epilepticus. Chest 126: 582–591.

Martella G, De Persis C, Bonsi P, Natoli S, Cuomo D, Bernardi G, Calabresi P, and Pisani A (2005) Inhibition of persistent sodium current fraction and voltage-gated L-type calcium current by propofol in cortical neurons: implications for its anti-epileptic activity. Epilepsia 46: 624–635.[CrossRef][Medline]

Nau C and Wang GK (2004) Interactions of local anesthetics with voltage-gated Na⁺ channels. J Membr Biol 201: 1–8.[CrossRef][Medline]

Orser BA, Wang LY, Pennefather PS, and MacDonald JF (1994) Propofol modulates activation and desensitization of GABA_A receptors in cultured murine hippocampal neurons. J Neurosci 14: 7747–7760.[Abstract]

Otoom SA and Hasan Z (2004) Propofol exhibits antiepileptic activity in hippocampal pyramidal neurons. Pharmacol Biochem Behav 77: 595–599.[CrossRef][Medline]

Prasad A, Worrall BB, Bertram EH, and Bleck TP (2001) Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 42: 380–386.[CrossRef][Medline]

Rafiq A, Zhang YF, DeLorenzo RJ, and Coulter DA (1995) Long-duration self-sustained epileptiform activity in the hippocampal-parahippocampal slice: a model of status epilepticus. J Neurophysiol 74: 2028–2042.[Abstract/Free Full Text]

Ragsdale DS and Avoli M (1998) Sodium channels as molecular targets for antiepileptic drugs. Brain Res Brain Res Rev 26: 16–28.[CrossRef][Medline]

Ragsdale DS, Mcphee JC, Scheuer T, and Catterall WA (1994) Molecular determinants of state-dependent block of Na⁺ channels by local-anesthetics. Science (Wash DC) 265: 1724–1728.[Abstract/Free Full Text]

Ragsdale DS, Mcphee JC, Scheuer T, and Catterall WA (1996) Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na⁺ channels. Proc Natl Acad Sci USA 93: 9270–9275.[Abstract/Free Full Text]

Rehberg B and Duch DS (1999) Suppression of central nervous system sodium channels by propofol. Anesthesiology 91: 512–520.[CrossRef][Medline]

Rogawski MA and Loscher W (2004) The neurobiology of antiepileptic drugs. Nature Rev Neurosci 5: 553–564.[CrossRef][Medline]

Rossetti AO, Reichhart MD, Schaller MD, Despland PA, and Bogousslavsky J (2004) Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 45: 757–763.[CrossRef][Medline]

Yarov-Yarovoy V, Brown J, Sharp EM, Clare JJ, Scheuer T, and Catterall WA (2001) Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na⁺ channel alpha subunit. J Biol Chem 276: 20–27.[Abstract/Free Full Text]

Yarov-Yarovoy V, Mcphee JC, Idsvoog D, Pate C, Scheuer T, and Catterall WA (2002) Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na⁺ channel alpha subunit in voltage-dependent gating and drug block. J Biol Chem 277: 35393–35401.[Abstract/Free Full Text]

This article has been cited by other articles:

				P. J. Jones, E. C. Merrick, T. W. Batts, N. J. Hargus, Y. Wang, J. P. Stables, E. H. Bertram, M. L. Brown, and M. K. Patel Modulation of Sodium Channel Inactivation Gating by a Novel Lactam: Implications for Seizure Suppression in Chronic Limbic Epilepsy J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 201 - 212. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: jpet.106.111542v1 320/2/828    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, P. J. Articles by Patel, M. K. Search for Related Content PubMed PubMed Citation Articles by Jones, P. J. Articles by Patel, M. K.